These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
33. Efficacy of combined anti-TNF-alpha and surgical therapy in perianal and enterocutaneous fistulizing Crohn's disease--clinical observations from a tertiary Eastern European center. Bor R; Farkas K; Bálint A; Szucs M; Ábrahám S; Baradnay G; Wittmann T; Szepes Z; Nagy F; Molnár T Scand J Gastroenterol; 2015 Feb; 50(2):182-7. PubMed ID: 25384713 [TBL] [Abstract][Full Text] [Related]
34. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338 [TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease. Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122 [TBL] [Abstract][Full Text] [Related]
36. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Walters TD; Kim MO; Denson LA; Griffiths AM; Dubinsky M; Markowitz J; Baldassano R; Crandall W; Rosh J; Pfefferkorn M; Otley A; Heyman MB; LeLeiko N; Baker S; Guthery SL; Evans J; Ziring D; Kellermayer R; Stephens M; Mack D; Oliva-Hemker M; Patel AS; Kirschner B; Moulton D; Cohen S; Kim S; Liu C; Essers J; Kugathasan S; Hyams JS; Gastroenterology; 2014 Feb; 146(2):383-91. PubMed ID: 24162032 [TBL] [Abstract][Full Text] [Related]
37. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies. Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953 [TBL] [Abstract][Full Text] [Related]
38. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease. Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028 [TBL] [Abstract][Full Text] [Related]